

## Cover Story

### Twin Pillars

*Patrick Clinton*

Editor-in-Chief

2003 was a great year for Roche, driven by the remarkable success of Pegasys. The company is staking its future, though, on the strategy of combining drugs and diagnostics.

70



George Abercrombie

**“Fuzeon is one of the most complex molecules ever manufactured. It takes six months and 100 steps to make a batch. Many skeptics said that it could never be done.”**

## Features

### Legal

Is Everyone a Target?

*Michael D. Lam*  
Associate Editor

Pfizer faces a whistleblower suit pressing a theory for Medicaid fraud that is untested but still scary.

56

### Strategy

The Ins and Outs of EAPs

*Wayne Dankner and Hua Dupré*  
Parexel International

Expanded access programs can generate good will and new data for companies—but careful planning is a must.

64

### GMPs

The Push for Modern Manufacturing

*Phillipe Cini and Ray Schneider*  
Tunnell Consulting

FDA's Process Analytical Technology Initiative is not just for new products.

86

### Marketing

DTC: European Style

*Frank Hone and Rob Benson*  
Healthworld Communications

US pharma marketers can learn a lot from Europe when it comes to building consumer demand for their products.

96

## News & Analysis

### Leading Indicators

#### News

Mark McClellan's shift to Medicare ... USDA to rewrite the rule book on genetically modified organisms ... A TAP sales manager is convicted of lying to a grand jury ... 100 companies to issue drug discount cards ... And a pioneering woman scientist gets her own university

23

#### Data

Prescription drug sales hit \$216 billion ... Consumers on RFID: Huh? ... Orphan drugs outpace the market.

34

#### Thought Leaders

Lise Kingo of Novo Nordisk on sustainability and corporate governance.

38

#### Washington Report

From FDA, a new guidance on communicating risk.

*Jill Wechsler*

42

#### European Report

A court decision aids the fight against parallel trade.

*Sarah Houlton, PhD*

46

#### Legal Forum

Judges seem likely to reject pharma's claim that AWP's are really just sticker prices.

*Michael D. Thompson*

50

#### At Issue

Independent contractors cut costs and offer flexibility—but they just might get you in trouble with the IRS.

*Andrew Schultz*

52

## Strategy & Tactics

#### Direct to Consumer

FDA's Peter Pitts discusses the new DTC draft guidance.

*Jill Wechsler*

108

#### Alternative Media

Three digital technologies you won't want to miss.

*Bill Drummy*

122

#### Marketing to Professionals

Instead of one detail per doctor, how about one "account manager" to serve the entire practice?

*Richard Vanderveer, PhD*

114

#### Medical Education

New rules and regs may require medical education communication companies to firewall their educational and promotional capabilities. Here's how one company did it.

*Joanna Breitstein*

126

#### Public Relations

Chandler Chicco discusses how PR programs can use viral and experiential marketing tactics.

*Joanna Breitstein*

118

## Insights

#### From the Editor

Billy Tauzin turned down a job at PhRMA, but that didn't stop him from giving the press some new ideas about the industry. Thank you, Billy.

*Patrick Clinton*

16

#### Back Page

The hysteria over SSRIs and kids buries the real story. The truth lies somewhere in the cold of numbers, not in the heat of emotions.

*Sibyl Shalo*

146

#### Letters to the Editor

18

## Resources

#### People Update

130

#### Calendar of Events

134

#### Advertisers Index

138